US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

West Pharmaceutical Services, Inc. Common Stock (NY:WST)

412.62 -4.05 (-0.97%)
Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about West Pharmaceutical Services, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call ↗
West Pharmaceutical Services (NYSE:WST) reported third-quarter results that exceeded its expectations, driven by continued demand for high-value product components, including those used in GLP-1... 
Via MarketBeat
Topics Earnings
News headline image
WST Q3 deep dive: Biologics and regulatory tailwinds fuel margin expansion, HVP mix shift continues
Healthcare products company West Pharmaceutical Services (NYSE:WST) announced better-than-expected revenue in Q3 2026, with sales up 8.7% year on year to $87... 
Via StockStory
S&P 500 Unusual Volume Movers for October 29, 2026 ↗
Via Chartmill
Topics Stocks
S&P 500 Top Movers: Today's US Session Gainers and Losers ↗
Via Chartmill
Topics Stocks
West Pharmaceutical Services (NYSE:WST) Q3 Beat and Raised Guidance Signal Strong Momentum ↗
Via Chartmill
News headline image
West (WST) Q3 2026 Earnings Call Transcript ↗
GLP-1 demand drives HVP components to 53% of revenue with 20% organic growth. 
Via The Motley Fool
Topics Earnings
S&P 500 Gap Movers: October 29, 2026 Session ↗
Via Chartmill
Topics Stocks
News headline image
West Pharmaceutical Services (NYSE:WST) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 8.7... 
Via StockStory
News headline image
West Pharmaceutical Services earnings: what to look for from WST
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results this Thursday morning. Here’s what to expect. West Ph... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Low-Volatility Stocks We’re Skeptical Of
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu... 
Via StockStory
Topics Economy
News headline image
1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
Topics Economy Firearms
News headline image
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Economy
News headline image
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Economy Stocks
News headline image
1 Surging Stock with Solid Fundamentals and 2 That Underwhelm
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
Topics Economy
News headline image
3 Profitable Stocks with Warning Signs
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Topics Economy Supply Chain
News headline image
1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Ignore
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
Topics Economy
News headline image
1 Mid-Cap Stock on Our Buy List and 2 Facing Headwinds
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco... 
Via StockStory
Topics Economy
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
Topics Economy
News headline image
3 Cash-Heavy Stocks We Approach with Caution
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
Topics Economy
News headline image
3 Reasons to Avoid WST and 1 Stock to Buy Instead
West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. T... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call
West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response re... 
Via StockStory
Topics Earnings
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC... 
Via StockStory
News headline image
WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.... 
Via StockStory
News headline image
West Pharmaceutical Services Q2 Earnings Call Highlights ↗
West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call ↗
West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide... 
Via Benzinga
Topics Earnings
These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8%... 
Via StockStory
Topics Economy
News headline image
West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect. W... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons WST is Risky and 1 Stock to Buy Instead
Over the past six months, West Pharmaceutical Services has been a great trade, beating the S&P 500 by 21.8%. Its stock price has climbed to $353.68, represen... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >